Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23963348)

1.

Is mode of presentation of B3 breast core biopsies (screen-detected or symptomatic) a distinguishing factor in the final histopathologic result or risk of diagnosis of malignancy?

Maclean GM, Courtney SP, Umeh H, Sanjeev S, McCormick C, Smith BM.

World J Surg. 2013 Nov;37(11):2607-12. doi: 10.1007/s00268-013-2191-6.

PMID:
23963348
2.

Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.

Noske A, Pahl S, Fallenberg E, Richter-Ehrenstein C, Buckendahl AC, Weichert W, Schneider A, Dietel M, Denkert C.

Hum Pathol. 2010 Apr;41(4):522-7. doi: 10.1016/j.humpath.2009.09.005. Epub 2009 Dec 11.

PMID:
20004938
3.

Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening.

Rakha EA, Lee AH, Jenkins JA, Murphy AE, Hamilton LJ, Ellis IO.

Int J Cancer. 2011 Sep 15;129(6):1417-24. doi: 10.1002/ijc.25801. Epub 2011 Feb 11.

PMID:
21128240
4.

Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3).

Lee AH, Denley HE, Pinder SE, Ellis IO, Elston CW, Vujovic P, Macmillan RD, Evans AJ; Nottingham Breast Team.

Histopathology. 2003 Apr;42(4):331-6.

PMID:
12653944
5.

Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening.

El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO.

Histopathology. 2008 Dec;53(6):650-7. doi: 10.1111/j.1365-2559.2008.03158.x.

PMID:
19076681
6.

Correlation of needle core biopsy with excision histology in screen-detected B3 lesions: the Merrion Breast Screening Unit experience.

Hayes BD, O'Doherty A, Quinn CM.

J Clin Pathol. 2009 Dec;62(12):1136-40. doi: 10.1136/jcp.2009.067280.

PMID:
19946101
7.

Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy.

Crisi GM, Mandavilli S, Cronin E, Ricci A Jr.

Am J Surg Pathol. 2003 Mar;27(3):325-33.

PMID:
12604888
8.

Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.

Carder PJ, Garvican J, Haigh I, Liston JC.

Histopathology. 2005 Mar;46(3):320-7.

PMID:
15720418
9.

Predictive value of breast lesions of "uncertain malignant potential" and "suspicious for malignancy" determined by needle core biopsy.

Dillon MF, McDermott EW, Hill AD, O'Doherty A, O'Higgins N, Quinn CM.

Ann Surg Oncol. 2007 Feb;14(2):704-11. Epub 2006 Dec 7.

PMID:
17151788
10.

Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy.

Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Mac Bride MB, Dilaveri CA, Wahner-Roedler DL, Ghosh K, Visscher DW.

Mayo Clin Proc. 2014 Apr;89(4):536-47. doi: 10.1016/j.mayocp.2014.02.004. Review.

PMID:
24684875
12.

Proliferative high-risk lesions of the breast: contribution and limits of US-guided core biopsy.

Zuiani C, Londero V, Bestagno A, Puglisi F, Di Loreto C, Bazzocchi M.

Radiol Med. 2005 Nov-Dec;110(5-6):589-602. English, Italian.

PMID:
16437044
13.

Management of patients diagnosed with lobular carcinoma in situ at needle core biopsy at a community-based outpatient facility.

Destounis SV, Murphy PF, Seifert PJ, Somerville PA, Arieno AL, Morgan RC, Young WL.

AJR Am J Roentgenol. 2012 Feb;198(2):281-7. doi: 10.2214/AJR.11.7043.

PMID:
22268169
14.

Improved malignancy prediction by B3 breast lesions subclassification.

de Be├ža FF, Rasteiro C, Correia A, Costa S, Amendoeira I.

Ann Diagn Pathol. 2013 Oct;17(5):434-6. doi: 10.1016/j.anndiagpath.2013.05.003. Epub 2013 Jun 15.

PMID:
23773891
15.

Screen-detected breast lesions with an indeterminate (B3) core needle biopsy should be excised.

Lieske B, Ravichandran D, Alvi A, Lawrence DA, Wright DJ.

Eur J Surg Oncol. 2008 Dec;34(12):1293-8. Epub 2007 Dec 26.

PMID:
18162359
16.

Application of the British National Health Service Breast Cancer Screening Programme classification in 226 breast core needle biopsies: correlation with resected specimens.

Pagni F, Bosisio FM, Salvioni D, Colombo P, Leone BE, Di Bella C.

Ann Diagn Pathol. 2012 Apr;16(2):112-8. doi: 10.1016/j.anndiagpath.2011.08.003. Epub 2011 Nov 4.

PMID:
22056037
17.

The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.

Barnes NL, Dimopoulos N, Williams KE, Howe M, Bundred NJ.

Eur J Surg Oncol. 2014 Mar;40(3):249-54. doi: 10.1016/j.ejso.2013.12.013. Epub 2014 Jan 3.

PMID:
24433818
18.

Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?

Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA.

Mod Pathol. 2003 Feb;16(2):120-9.

19.

Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS).

Kluttig A, Trocchi P, Heinig A, Holzhausen HJ, Taege C, Hauptmann S, Boecker W, Decker T, Loening T, Schmidt-Pokrzywniak A, Thomssen C, Lantzsch T, Buchmann J, Stang A.

BMC Cancer. 2007 Jun 14;7:100.

20.

Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3).

Houssami N, Ciatto S, Bilous M, Vezzosi V, Bianchi S.

Br J Cancer. 2007 Apr 23;96(8):1253-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk